Hepatocellular Carcinoma
The primary cancer of the liver, almost always arising in cirrhotic patients, diagnosed via dynamic imaging and treated by resection, ablation, or transplant.
Emergency Management: Tumor rupture requiring emergent transarterial embolization to achieve hemostasis. Variceal bleeding requiring emergent endoscopy and banding.
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver, originating from hepatocytes. It almost exclusively develops in the setting of chronic liver inflammation and cirrhosis, making it a classic example of inflammation-driven oncogenesis.
Detailed Overview
HCC is a leading cause of cancer-related death globally. Its pathophysiology is deeply intertwined with chronic liver injury, most notably from Hepatitis B (HBV), Hepatitis C (HCV), alcohol use disorder, and non-alcoholic steatohepatitis (NASH). The continuous cycle of hepatocellular necrosis and regeneration in a fibrotic environment leads to genomic instability and malignant transformation. A unique feature of HCC is that it can often be diagnosed via characteristic vascular patterns on dynamic imaging without the need for biopsy. Because HCC arises in diseased livers, prognosis and treatment depend simultaneously on tumor stage and the severity of underlying hepatic dysfunction.
Epidemiology & Demographics
Incidence: 6th most common cancer worldwide. Age distribution: Typically occurs in late adulthood (60-70 years) in Western countries, but much earlier (30-40 years) in endemic HBV regions (Asia/Africa). Gender ratio: Male predominant (3:1).
Etiological Mechanism
Malignant transformation of hepatocytes driven by chronic inflammation, viral DNA integration (in HBV), and continuous cellular turnover in the setting of cirrhosis.
Primary Causes
Primary: Chronic Hepatitis B (can cause HCC without cirrhosis) and Hepatitis C (requires cirrhosis)
Secondary: Alcoholic cirrhosis, Non-alcoholic fatty liver disease (NAFLD/NASH), Hemochromatosis, Aflatoxin B1 exposure
HCC development is a multistep process resulting from chronic liver injury. Continuous necrosis and regeneration lead to telomere shortening and chromosomal instability. Viral factors play a role: HBV integrates into the host genome, disrupting tumor suppressor genes and expressing oncogenic X protein. Molecularly, common mutations include TERT promoter mutations (maintaining telomerase activity), TP53 mutations (especially with Aflatoxin exposure), and activation of the Wnt/beta-catenin pathway. As hepatocytes transform into dysplastic nodules and then frank HCC, their blood supply shifts. Normal liver gets 75% of blood from the portal vein and 25% from the hepatic artery. HCC undergoes neoangiogenesis, deriving its blood supply almost exclusively from the hepatic artery. This unique arterialization is the basis for its radiologic diagnosis and therapies like transarterial chemoembolization (TACE).
Diagnostic Criteria & Guidelines
In an at-risk patient (cirrhosis or chronic HBV), HCC can be diagnosed non-invasively if multiphasic CT/MRI shows the classic LIRADS-5 pattern: arterial phase hyperenhancement with subsequent portal venous/delayed phase 'washout'. Biopsy is reserved for atypical lesions to avoid needle-track seeding.
For early stage (BCLC 0/A): Surgical resection (if liver function is excellent, Child-Pugh A without portal hypertension) OR Liver Transplantation (if meeting Milan Criteria: 1 lesion <= 5 cm, or up to 3 lesions each <= 3 cm) OR Radiofrequency Ablation (RFA).
Second-Line & Adjunctive Therapy
For intermediate stage (BCLC B): Transarterial Chemoembolization (TACE). For advanced stage (BCLC C, vascular invasion): Systemic immunotherapy/targeted therapy with Atezolizumab + Bevacizumab, or Sorafenib/Lenvatinib.
Surgical & Procedural Management
Partial hepatectomy or orthotopic liver transplantation. Transplantation cures both the tumor and the underlying cirrhotic liver.
Patient Counseling & Advice
Discuss the dual nature of the illness: managing both the cancer and the failing liver. Emphasize the importance of adherence to antiviral therapies for Hep B/C if applicable. If on a transplant list, discuss strict adherence to screening and lifestyle rules.
Follow-Up & Monitoring Schedule
Post-resection/ablation: Multiphasic CT or MRI of the liver + AFP every 3-6 months. Cirrhotics without HCC require US screening + AFP every 6 months lifelong.
Preventive Strategies
Universal Hepatitis B vaccination. Curative DAA therapy for Hepatitis C. Treatment of underlying causes of cirrhosis (alcohol cessation, weight loss for NASH).
Highly dependent on stage at diagnosis. Early stage treated with transplant has a >70% 5-year survival rate. Advanced stage treated systemically has a median survival of 1-2 years. Terminal stage survival is 3-4 months.